USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Molecular Oncology Inc
Address:
19 Firstfield Rd
Gaithersburg, MD 20878
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $503,850.00 10
SBIR Phase II $1,344,212.00 3

Award List:

MALIGNANCY-SPECIFIC GENE EXPRESSION IN BREAST CANCER

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
In 20 to 40 percent of human breast cancers, the erbb-2 or neu gene is amplified, leading to mrna and protein overexpression. amplification of the egf receptor gene is rare, but overexpression of the egf receptor has been shown to occur without accompanying gene amplification. overexpression of… More

DOMAIN-SPECIFIC ANTIBODIES TO HUMAN ERB-2/NEU PROTEIN

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$44,074.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

SYNTHETIC VACCINES: TEST OF CONCEPTS AND APPLICATION TO RIFT VALLEY FEVER VIRUS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$59,777.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Marc S Collett
Abstract:
N/a

DOMAIN-SPECIFIC ANTIBODIES TO HUMAN ERB-2/NEU PROTEIN

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$447,480.00
Agency:
HHS
Principal Investigator:
Abstract:
In 20 to 40 percent of human breast cancers, the erbb-2 or neu gene is amplified, leading to mrna and protein overexpression. this overexpression is likely to be involved in either the initiation or progression of these tumor cells. amplification of the erbb-2 gene has been linked to a poorer… More

ANTIBODIES TO HUMAN NM23: A POTENTIAL MARKER OF MALIGNANCY

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Charles R King
Abstract:
N/a

SYNTHETIC VACCINES: TEST OF CONCEPTS AND APPLICATION TO RIFT VALLEY FEVER VIRUS

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$396,732.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Marc S Collett
Abstract:
Use of synthetic peptides, comprising both b and t cell determinants, is being considered a viable approach to vaccine development. we will explore the suitability of this strategy employing rift valley fever virus (rvfv) as the study model. the immunogenicity of synthetic peptides representing… More

ANTIBODIES TO HUMAN NM23: A POTENTIAL MARKER OF MALIGNANCY

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Charles R King
Abstract:
For many types of cancer, patient morbidity-and ultimately mortality-is due to the development of metastatic lesions. experimental evidence suggests that tumors can inherently differ in their ability to form metastasis. as yet there isno available test to determine if particular human tumors are of… More

LS-MET-1, A HIGHLY METASTATIC HUMAN CARCINOMA CELL LINE

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Turner, Nancy A , Principal Investigator
Abstract:
Metastasis from tumors of epithelial origin such as the lung, colon, breast, and prostate constitute the cause of the majority of cancer related deaths. there exist few experimental systems suitable for the testing of anti-metastatic agents on human epithelial tumors. while many cell lines form… More

HUMAN COLLAGENASE IV AND ITS INHIBITORS

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Bird, Robert E , Principal Investigator
Abstract:
The degradation of the collagen type iv network in basement membranes is a critical event in many normal and pathological conditions including tissue remodelling, wound healing, tumor cell metastasis, and angiogenesis. the 72 kd type iv collagenase is a neutral metalloprotease capable of degrading… More

ANTIBODIES TO HUMAN TYPE IV COLLAGENASE AND ITS INHIBITOR

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,999.00
Agency:
HHS
Principal Investigator:
Chi-ming Liang
Abstract:
The degradation of basement membrane is important for leukocyte migration, tissue remodeling, wound healing, angiogenesis and tumor invasion. type iv collagen, the major component of basem nt membrane, is degraded by type iv collagenase (civase) which usually exists in a latent form. the latent… More

EXPRESSION OF ENZYMES AND INHIBITORS OF METASTASIS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Rafael A Fridman
Abstract:
Degradation of collagen iv in basement membranes has been implicated in the pathogenesis of metastasis, and in the process of angiogenesis. the 72 kd and the 92 kd type iv collagenases are metalloproteases capable of degrading collagen iv which have been suggested to play a critical role in the… More

BISPECIFIC SINGLE CHAIN ANTIBODY VARIABLE REGIONS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert E Bird
Abstract:
Molecules that contain two distinct antigen binding domains, bispecific antibodies, have shown promise as movel anti-cancer therapeutic agents. to datte, such bispecific antibodies have been prepared by two methods. the fusion of two hybridoma cell lines, one of which produces an anti-tumor antibody… More

MECHANISTIC APPRAOCH FOR DESIGN OF ANTI-METASTASIS DRUGS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Nancy A Turner
Abstract:
The goal of the project is to develop new organic compounds that have specific anti-metastatic activity for use in adjuvant treatment of cancer patients to inhibit or delay the development of metastatic disease. inhibition of basement membrane degradation, an important event in the metastatic… More